Cipla is currently trading at Rs. 567.75, up by 4.30 points or 0.76% from its previous closing of Rs. 563.45 on the BSE.
The scrip opened at Rs. 566.00 and has touched a high and low of Rs. 569.90 and Rs. 566.00 respectively. So far 2389 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 678.00 on 19-Sep-2018 and a 52 week low of Rs. 483.75 on 29-Jan-2019.
Last one week high and low of the scrip stood at Rs. 580.30 and Rs. 544.00 respectively. The current market cap of the company is Rs. 45399.54 crore.
The promoters holding in the company stood at 36.70%, while Institutions and Non-Institutions held 40.81% and 22.49% respectively.
Cipla has signed an agreement to acquire 26% stake on a fully diluted basis in AMPSolar Power Systems. In line with Cipla's commitment to enhance the proportion of renewable (solar) based power consumption and to comply with regulatory requirement for captive power consumption under electricity laws, Cipla will acquire and maintain 26% stake on a fully diluted basis in AMPSolar throughout the term of the Power Purchase Agreement.
Post-acquisition, AMPSolar will become an associate of Cipla. The subscription of equity shares and compulsorily convertible debentures in one or more tranches upto the actual commercial operation date which is tentatively May 30, 2020.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: